MV-012-968 / Meissa Vaccines - LARVOL DELTA

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months (clinicaltrials.gov) - P1c | N=63 | Recruiting | Sponsor: Meissa Vaccines, Inc. | N=45 ➔ 63 | Trial completion date: Oct 2022 ➔ Oct 2023 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Enrollment change • Trial completion date • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (clinicaltrials.gov) - P2a; N=60; Completed; Sponsor: Meissa Vaccines, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (clinicaltrials.gov) - P1b; N=34; Completed; Sponsor: Meissa Vaccines, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-24 Months (clinicaltrials.gov) - P1c; N=45; Recruiting; Sponsor: Meissa Vaccines, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-24 Months (clinicaltrials.gov) - P1c; N=45; Not yet recruiting; Sponsor: Meissa Vaccines, Inc.

Clinical • New P1 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (clinicaltrials.gov) - P2a; N=60; Active, not recruiting; Sponsor: Meissa Vaccines, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (clinicaltrials.gov) - P2a; N=70; Recruiting; Sponsor: Meissa Vaccines, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Respiratory Diseases

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (clinicaltrials.gov) - P2a; N=70; Not yet recruiting; Sponsor: Meissa Vaccines, Inc.

Clinical • New P2a trial • Infectious Disease • Respiratory Diseases

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (clinicaltrials.gov) - P1b; N=42; Active, not recruiting; Sponsor: Meissa Vaccines, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Respiratory Diseases

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (clinicaltrials.gov) - P1b; N=42; Recruiting; Sponsor: Meissa Vaccines, Inc.; N=30 ➔ 42

Clinical • Enrollment change • Infectious Disease • Respiratory Diseases

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Meissa Vaccines, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Meissa Vaccines, Inc.

Clinical • New P1 trial • Infectious Disease

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Meissa Vaccines, Inc.; Enrolling by invitation ➔ Active, not recruiting

Clinical • Enrollment closed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults (clinicaltrials.gov) - P1; N=20; Enrolling by invitation; Sponsor: Meissa Vaccines, Inc.

Clinical • New P1 trial